Breaking Finance News

Puretech Health Plc (LON:PRTC) target price held steady at 206.00GBX, reported today by Numis

Puretech Health Plc (LON:PRTC) had its estimated target price hold steady to 206GBX by Numis in a report released 8/16/2016. The target price indicates a potential upside of 0.32% based on the bussiness’ previous stock close price.

Previously on Monday August 1 2016, Peel Hunt released a statement about Puretech Health Plc(LON:PRTC) raised the target price at 220.00GBX. At the time, this indicated a possible upside of 0.50%.

Having a price of 156.50GBX, Puretech Health Plc (LON:PRTC) traded 9.15% higher on the day. With the last stock price up 17.63% from the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the date range. Puretech Health Plc has registered a 50-day average of 154.87GBX and two hundred day average of 144.52GBX. Volume of trade was was up over the average, with 195,229 shares of PRTC changing hands over the typical 56,305 shares.

See Graphic Below:

Puretech Health Plc (LON:PRTC)

Puretech Health Plc has a 52 week low of 118.00GBX and a 52 week high of 177.00GBX. Puretech Health Plc’s market cap is currently 0.0 GBX.

Also covering Puretech Health Plc’s price target, a total of 5 firms have released a ratings update on Puretech Health Plc. The average target stock price is 2.95GBX with four firms rating the stock a strong buy, one firm rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and finally 0 firmsrating the company as sell.

Brief Synopsis About Puretech Health Plc (LON:PRTC)

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, and LLC and Knode Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *